$ILMN

Ericksen Scott D sold $80K of ILMN

Ericksen Scott D (VP, Chief Accounting Officer) sold 500 shares of ILLUMINA, INC. (ILMN) at $160.00 on 2026-05-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ericksen Scott D
Published Jun 1, 2026, 8:27 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ILMN
Neutral
high confidence
Mentioned
$ILMN
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNNeutralLow
01

Why it matters

The disclosure updates the insider activity record but does not provide new company fundamentals, guidance, or deal information.

02

Market read

Traders may note the sale for sentiment monitoring, but the 10b5-1 structure makes it unlikely to drive a durable repricing alone.

03

What to watch

The filing does not indicate why the sale occurred (taxes, diversification, scheduled liquidity), so interpreting it as bearish may be overstated.

Relevance 3/10Novelty 2/10Timing: Filed June 1; sale executed May 29 under a 10b5-1 plan.

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by the Chief Accounting Officer under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$ILMNNeutralHigh confidence
Context

Illumina CFO sold $80K of ILMN shares in an open-market transaction under a pre-arranged 10b5-1 plan on May 29.

Expected impact

Likely limited near-term impact; any effect should fade unless accompanied by other negative company-specific news.

Evidence & confidence

The filing is a routine officer sale with explicit 10b5-1 pre-arrangement, reducing interpretive value versus discretionary selling.

Market effects

Minimal; this is company-specific insider transaction with no stated operational/financial change.

None indicated.

None indicated.

Counterpoint

Even 10b5-1 sales can coincide with periods of elevated uncertainty; traders may still watch for clustering of insider sales around catalysts.

Key entities

  • Illumina, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Ericksen Scott D

    VP, Chief Accounting Officer who sold 500 shares.

Related articles

$ILMNHighAI 9/10

Illumina (ILMN) Q2 2026 Earnings Call Transcript

Illumina (ILMN) reported Q2 2026 revenue of $1.16B, up 9.5% YoY, and non-GAAP EPS of $1.31. Clinical consumables and NovaSeq X placements drove results. Gross margin was 68.2%. Full-year 2026 guidance was raised to $4.60B-$4.64B revenue and $5.30-$5.40 EPS. Cash was $1.17B vs $1.99B debt.

$ILMNHighAI 9/10

Illumina (ILMN) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Head of Investor Relations - Conor McNamara Chief Executive Officer - Jacob Thaysen Chief Financial Officer - Ankur Dhingra TAKEAWAYS Total Revenue -- $1.16 billion, representing a 9.5% increase year over year driven by clinical market demand and the NovaSeq X expansion. Rest of World Organic Revenue -- Increased 8.1% year over year, exceeding the high end of management's previous guidance.

$ILMNMedAI 8/10

Illumina (NASDAQ:ILMN) Surprises With Q2 CY2026 Sales, Full

Genomics company Illumina (NASDAQ: ILMN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. The company’s full-year revenue guidance of $4.62 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.31 per share was 6.8% above analysts’ consensus estimates. Is now the time to buy Illumina? Find out by accessing our full research report, it’s free.

$ILMNHigh

ILLUMINA, INC. (ILMN): Results of Operations and Financial Condition

ILLUMINA, INC. (ILMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q226earningsrelease.htm EX-99.1 Document Investors: Conor McNamara +1.858.291.6421 ir@illumina.com Media: Christine Douglass pr@illumina.com Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026 San Diego, July 30, 2026 /PRNewswire/ -- Illumina, Inc.